Stock Yards Bank & Trust Co. Has $13.27 Million Stock Position in Zoetis Inc. $ZTS

Stock Yards Bank & Trust Co. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 90,657 shares of the company’s stock after selling 10,904 shares during the period. Stock Yards Bank & Trust Co.’s holdings in Zoetis were worth $13,265,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ZTS. Halbert Hargrove Global Advisors LLC grew its position in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the last quarter. REAP Financial Group LLC boosted its stake in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares in the last quarter. NewSquare Capital LLC grew its holdings in shares of Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the last quarter. ORG Partners LLC grew its holdings in shares of Zoetis by 56.8% during the second quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after purchasing an additional 84 shares during the last quarter. Finally, Financial Consulate Inc. bought a new position in Zoetis in the 3rd quarter valued at approximately $39,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

ZTS stock opened at $123.24 on Wednesday. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The firm has a market cap of $54.31 billion, a price-to-earnings ratio of 20.75, a PEG ratio of 2.53 and a beta of 0.97. The company’s fifty day simple moving average is $123.37 and its 200 day simple moving average is $138.85. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue was up .5% compared to the same quarter last year. During the same period last year, the business posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s payout ratio is presently 33.67%.

Analysts Set New Price Targets

Several research firms recently commented on ZTS. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research report on Thursday, December 18th. JPMorgan Chase & Co. cut their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. HSBC set a $140.00 price objective on Zoetis in a report on Wednesday, December 10th. UBS Group lowered their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Finally, KeyCorp assumed coverage on Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average price target of $160.18.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.